PSDV licences the platform drug delivery system to Alimera. The platform is a system that delivers .02 micrograms/day of a steroid to treat DME, in the form of a very small tube. DME is an eye disease that has no approved treatment. This platform is truly cutting edge, however it delivers a steroid; arguably a concern for the FDA. PSDV now has many pending platforms to deliver different kinds of drugs over a variable periods of time, from 6 months to 3 years. They now have PFE as a ten percent owner and J&J as an investor in the delivery systems for back of the eye diseases. The idea is: if you can deliver drugs safely to the back of the eye, why not the brain, the joints, or the heart? Now read about it, it has tremendous potential.